Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03945760 · ClinicalTrials.gov registry record · Early Phase 1
Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects
A Early Phase 1 study of Allergic Contact Dermatitis, sponsored by Wright State Physicians.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT03945760: Completed Early Phase 1 study of Allergic Contact Dermatitis, sponsored by Wright State Physicians.
NCT03945760 is a Early Phase 1 study of Allergic Contact Dermatitis that has completed, run by Wright State Physicians. The registered enrollment target is 23 participants, roughly in line with the 24-participant average among 3 other Allergic Contact Dermatitis trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03945760, a Early Phase 1 study of Allergic Contact Dermatitis, has completed, sponsored by Wright State Physicians.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The treatment of allergic contact dermatitis (ACD) can be unsatisfactory, and that other skin diseases such as atopic dermatitis have an increased likelihood of ACD, improved systemic treatments are needed. This research study explores the effectiveness of Baricitinib in treating Delayed-Type Hypersensitivity (allergic) versus Irritant Skin reactions. Subjects for this study need to be healthy males between the ages of 18 and 40. This study will evaluate this by injecting antigens as well as applying them on top of the skin to the forearm then measure the effects of Baricitinib by skin and blood testing.
Primary Outcome
Investigator will assess the skin inflammation reduction as measured by erythema associated with DTH versus irritant skin reactions.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Baricitinib
Study Locations (1)
Ohio
- Wright State Physicians - Fairborn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2023-10-16 |
| Phase | Early Phase 1 |
What the finished NCT03945760 record still lists
NCT03945760 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, roughly in line with the 24-participant average among 3 other Allergic Contact Dermatitis trials with a reported enrollment target.
The record links to 1 condition, with Allergic Contact Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03945760 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03945760 about?
NCT03945760 is a clinical study titled "Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects". The treatment of allergic contact dermatitis (ACD) can be unsatisfactory, and that other skin diseases such as atopic dermatitis have an increased likelihood of ACD, improved systemic treatments are needed. This research study explores the effectiveness of Baricitinib in treating Delayed-Type Hyper...
What is the current status of trial NCT03945760?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 23 participants. The study started on 2020-09-14. Estimated completion is 2023-10-16.
What conditions does trial NCT03945760 study?
This clinical trial studies the following conditions: Allergic Contact Dermatitis.
What interventions are being tested in trial NCT03945760?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).
Who is sponsoring clinical trial NCT03945760?
This trial is sponsored by Wright State Physicians, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03945760 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Contact Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI